BURNING ROCK BIOTECH LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.85 USD | -0.01% |
|
+18.06% | -8.60% |
| 04-02 | Earnings Flash (BNR.L) BURNING ROCK BIOTECH Posts FY23 Revenue $75.7M | MT |
| 04-02 | Earnings Flash (BNR.L) BURNING ROCK BIOTECH Posts FY23 Loss $-0.90 | MT |
| Sales 2021 | 508M 70.09M 5.61B | Sales 2022 | 563M 77.73M 6.22B | Capitalization | 1.63B 225M 18.04B |
|---|---|---|---|---|---|
| Net income 2021 | -797M -110M -8.81B | Net income 2022 | -971M -134M -10.73B | EV / Sales 2021 | 9.68 x |
| Net cash position 2021 | 1.41B 195M 15.59B | Net cash position 2022 | 857M 118M 9.47B | EV / Sales 2022 | 1.38 x |
| P/E ratio 2021 |
-7.92
x | P/E ratio 2022 |
-1.66
x | Employees | - |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 62.79% |
More Fundamentals
* Assessed data
More news
Latest transcript on Burning Rock Biotech Limited
More press releases
| 1 day | -0.01% | ||
| 1 week | +18.06% | ||
| Current month | +16.74% | ||
| 1 month | +21.43% | ||
| 3 months | -0.82% | ||
| 6 months | -20.56% | ||
| Current year | -8.60% |
1 week
0.76
0.89
1 month
0.680.89
Current year
0.571.00
1 year
0.573.25
3 years
0.5738.64
5 years
0.5739.75
10 years
0.5739.75
| Managers | Title | Age | Since |
|---|---|---|---|
Simon Wu
FOU | Founder | - | 31/12/13 |
Yu Sheng Han
CEO | Chief Executive Officer | 46 | 31/12/13 |
Leo Li
DFI | Director of Finance/CFO | 40 | 31/12/18 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Feng Deng
BRD | Director/Board Member | 61 | 31/07/16 |
Yu Sheng Han
CEO | Chief Executive Officer | 46 | 31/12/13 |
Gang Lu
BRD | Director/Board Member | 53 | 31/05/14 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.64% | 4 M€ | -27.92% | ||
| 0.02% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 0.85 | -0.01% | 30,335 |
| 25/04/24 | 0.85 | +3.56% | 42,703 |
| 24/04/24 | 0.8208 | -4.45% | 8,004 |
| 23/04/24 | 0.859 | -0.12% | 29,271 |
| 22/04/24 | 0.86 | +19.44% | 63,907 |
Delayed Quote Nasdaq, April 26, 2024 at 09:30 pm
More quotes
Burning Rock Biotech Ltd is a holding company mainly engaged in the next generation sequencing (NGS) based cancer therapy selection. The Company operates three segments. Central Laboratory Business segment is engaged in the sales of cancer therapy selection test to individual patients. In-Hospital Business segment is engaged in the sales of reagent kits and the provision of the facilitation services for the sale of laboratory equipment to hospitals. Pharma Research and Development Services segment provide services to companies primarily in relation to the development of targeted therapies and immunotherapies for various types of cancer, and to hospitals for their studies on cancer diagnosis and treatment. Its products include OncoScreen Plus and LungPlasma. Its NGS-based cancer therapy selection tests applicable to a broad range of cancer types, including lung cancer, prostate cancer, breast cancer and others. The Company mainly conducts its businesses in the China market.
Calendar
27/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -8.60% | 89.62M | |
| -17.89% | 8.25B | |
| +39.20% | 3.57B | |
| -39.11% | 2.46B | |
| -8.06% | 2.46B | |
| -7.35% | 2.38B | |
| -12.61% | 1.81B | |
| -19.01% | 1.55B | |
| -40.66% | 1.21B | |
| +7.56% | 1.11B |
- Stock Market
- Equities
- BNR Stock
